TipRanks on MSN
Vistagen’s Phase 3 Trial of Fasedienol Nasal Spray: A Potential Game-Changer for Anxiety Treatment
Vistagen Therapeutics Inc. (($VTGN)) announced an update on their ongoing clinical study. Vistagen Therapeutics Inc. is conducting a Phase 3 ...
A one-week, clinician-supported online therapy program significantly reduced anxiety and improved daily functioning for ...
TipRanks on MSN
Vanda Pharmaceuticals Advances with Promising Social Anxiety Disorder Treatment Study
Vanda Pharmaceuticals ((VNDA)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, ...
The program in question is Neuphoria’s BNC210, also known as soclenicant, an α7 nicotinic receptor negative alteration ...
The company is dropping its social anxiety disorder program but will still test the molecule in post-traumatic stress ...
Neuphoria Therapeutics Inc.’s phase III study of social anxiety disorder has missed its primary and secondary endpoints, ...
AFFIRM-1 trial did not meet primary endpoint or secondary endpoints Company to conduct strategic review of portfolio and business operations BURLINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ...
Generalized anxiety disorder affects millions, often trapping sufferers in cycles of fear and isolation that conventional ...
All products featured on Self are independently selected by our editors. However, we may receive compensation from retailers and/or from purchases of products through these links. Feeling nervous or ...
Lynx1 Capital Management LP, a ten percent owner of Neuphoria Therapeutics Inc. (NASDAQ:NEUP), reported purchasing 639,110 shares of common stock on October 21, 2025. The company has shown remarkable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback